Will Lewis

“Today's updates are intended to illustrate three overarching ideas. The first is that Insomed has evolved into a diversified biotechnology company that we believe can generate significant revenue and earnings with substantial growth over the next 10 years and beyond.”

“Yeah, well, you know, I'll just start out by saying this launch has blown away all our expectations.”

“I want to start off today's call by framing what I believe are our two key accomplishments this quarter, operational excellence and positioning for our future. across our commercial clinical and research efforts we've demonstrated exceptional operating performance this has laid the groundwork for insmed's potential…”

“Everything is on track or ahead of our internal benchmarks, and that gives us great conviction in the guidance we've provided both for the year and for peak sales for Brinsupri and, more broadly, for Eric Hayes, for TPIP.”

“When we put out the additional information, our intention, which obviously did not go as planned, was to provide the anchor points for what is currently one of the strongest launches in recent years.”